De Novo Generation of Hit-like Molecules from Gene Expression Signatures Using Artificial Intelligence

Abstract

Finding new molecules with a desired biological activity is an extremely difficult task. In this context, artificial intelligence and generative models have been used for molecular <i>de novo</i> design and compound optimization. Herein, we report the first generative model that bridges systems biology and molecular design conditioning a generative adversarial network with transcriptomic data. By doing this we could generate molecules that have high probability to produce a desired biological effect at cellular level. We show that this model is able to design active-like molecules for desired targets without any previous target annotation of the training compounds as long as the gene expression signature of the desired state is provided. The molecules generated by this model are more similar to active compounds than the ones identified by similarity of gene expression signatures, which is the state-of-the-art method for navigating compound-induced gene expression data. Overall, this method represents a novel way to bridge chemistry and biology to advance in the long and difficult road of drug discovery.

Cell Morphology-Guided De Novo Hit Design by Conditioning Generative Adversarial Networks on Phenotypic Image Features

“…Molecular Embedding: Recent studies have shown that is possible to encode molecules (as SMILES 34,44,45 , graphs or SELFIES 36 ) into a continuous representations. As before 34,45,46 , we used a molecular autoencoder but in this case it learns to encode SELFIES of a molecule (as one-hot encoding) into a continuous latent vector, which then can be decoded back into SELFIES. The architecture of this model is based on the previous work of Winter et al 34,45 ,…”

Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions

“…In brief, the DINGOS algorithm combines a rule‐based approach with an ML model trained on known successful synthetic routes, while the former ensures the synthesizability and the later provides a directed approach to limiting the output molecules to compounds with desirable similarity to the template. Another remarkable ML‐based generative approach is proposed by Méndez‐Lucio et al, 261 which bridges systems biology and molecular design. To our knowledge, it is the first AI/ML‐based drug design tool that combines transcriptomic and structural data.…”

Artificial Intelligence Effecting a Paradigm Shift in Drug Development

“…Mendez-Lucio et al of Bayer combined GAN with transcriptomic data and demonstrated its capabilities in proposing hit molecules based on a gene expression signature of the target knockout. 56 This approach was based on the concept that a knocked-out protein would generate a gene expression signature that is analogous to the pharmacological inhibition of the same target. This platform could be applied to any target, as no prior background information on it or its active molecules are required.…”